$The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis$

The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis

To evaluate the changes in anti cyclic citrullinated peptide (Anti-CCP) antibodies, rheumatoid factor (RF), interleukins 17 and 10 (IL-17 and IL-10), high sensitivity C- reactive protein (hs CRP) and T regulatory cells (Treg) count following an anti TNF-α biological agent (etanercept) therapy in pa...

Full description

Bibliographic Details
Main Authors:	Madha Mohammed Sheet, Laith Abdul-Elah Kamel, Jamal Nasser Farhood
Format:	Article
Language:	English
Published:	College of Pharmacy / Mustansiriyah University 2014-06-01
Series:	Al-Mustansiriyah Journal of Pharmaceutical Sciences
Subjects:	rheumatoid arthritis, IL-17, etanercept, Treg, TNF-α
Online Access:	https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/121

Similar Items

Immunologic Parameters for Disease Activity in Rheumatoid Arthritis
by: E Riyadh Mohsen, et al.
Published: (2021-10-01)

Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-α inhibitors in Iraqi patients with rheumatoid arthritis
by: Abdullah Abbas Awni, et al.
Published: (2023-06-01)

Terapia com anti-TNF na amiloidose renal em artrite reumatoide refratária: uma nova perspectiva terapêutica Anti-TNF therapy in renal amyloidosis in refractory rheumatoid arthritis: a new therapeutic perspective
by: Christiane Aguiar Nobre, et al.
Published: (2010-04-01)

Etanercept in the treatment of Graves’ ophthalmopathy with primary hypothyroidism and rheumatoid arthritis
by: Olivera Boskovic, et al.
Published: (2020-01-01)

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
by: Hisashi Yamanaka, et al.
Published: (2019-12-01)

TNFα-Signaling Modulates the Kinase Activity of Human Effector Treg and Regulates IL-17A Expression
by: Paulo C. M. Urbano, et al.
Published: (2020-01-01)

Efficacy and safety of the biosimilar etanercept in the treatment of patients with rheumatoid arthritis and spondyloarthritis
by: B. G. Issayeva, et al.
Published: (2024-10-01)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
by: Yoshiya Tanaka, et al.
Published: (2019-07-01)

Association between genetic polymorphism in tumor necrosis factor-alpha gene and adverse effects of etanercept in rheumatoid arthritis patients
by: Samer Imad Mohammed, et al.
Published: (2023-09-01)

Distinct therapeutic effects of auraptene and umbelliprenin on TNF-α and IL-17 levels in a murine model of chronic inflammation
by: Saeid Joveini, et al.
Published: (2024-12-01)

Influence of promoter polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) genes on therapeutic response to etanercept in rheumatoid arthritis
by: Jančić Ivan, et al.
Published: (2015-01-01)

Epidemiological and Clinical Factors Affecting the Response to Etanercept Among Patients with Rheumatoid Arthritis
by: Samer Imad Mohammed, et al.
Published: (2022-06-01)

Treatment in Patients with Psoriatic Disease and Rheumatoid Arthritis: Seven Case Reports
by: Tomoko Akeda, et al.
Published: (2023-01-01)

ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients
by: Kim HJ, et al.
Published: (2020-03-01)

The Effect of TNF-Alpha Gene Polymorphisms At -376 G/A, -806 C/T, and -1031 T/C on The Likelihood of Becoming a Non-Responder to Etanercept in A Sample of Iraqi Rheumatoid Arthritis Patients
by: Samer Imad Mohammed, et al.
Published: (2022-12-01)

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
by: Yen-Ju Lin, et al.
Published: (2020-04-01)

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis
by: Szilárd Póliska, et al.
Published: (2019-04-01)

No effect of anti-TNF-α treatment on serum IL-17 in patients with rheumatoid arthritis
by: Dorota Sikorska, et al.
Published: (2018-10-01)

Effectiveness of Combination of Leflunomide and Methotrexate compared to Etanercept in the Treatment of Rheumatoid Arthritis: A systematic review and meta-analysis
by: Rashin Iman, et al.
Published: (2021-07-01)

Etanercept Inhibits B Cell Differentiation by Regulating TNFRII/TRAF2/NF-κB Signaling Pathway in Rheumatoid Arthritis
by: Xiao-Yu Cai, et al.
Published: (2020-05-01)

Predictors of Response to (Etanercept) in the Treatment of Iraqi Patients with Active Rheumatoid Arthritis
by: Nizar A. Jassim
Published: (2015-04-01)

Proinflammatory cytokines profile in patients with Rheumatoid arthritis
by: Shahlaa M. Saleh, et al.
Published: (2009-04-01)

Leonurine Regulates Treg/Th17 Balance to Attenuate Rheumatoid Arthritis Through Inhibition of TAZ Expression
by: Yan-Yi Du, et al.
Published: (2020-10-01)

Role of TNFα and IL-10 in rheumatoid arthritis and association with some HLA II DR and DQ alleles
by: N. Alsalih, et al.
Published: (2020-05-01)

An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
by: Alexander Vugler, et al.
Published: (2022-11-01)

Is interleukin-17 implicated in early knee osteoarthritis pathogenesis as in rheumatoid arthritis?
by: Hoda M. Abdel-Naby, et al.
Published: (2022-05-01)

IL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis
by: Natalia A. Lapkina, et al.
Published: (2024-09-01)

Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα Immediate complications of 3,555 injections of anti-TNFα
by: Júlio César Bertacini de Moraes, et al.
Published: (2010-04-01)

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
by: Alexander Vugler, et al.
Published: (2024-10-01)

Extract from mango mistletoes Dendrophthoe pentandra ameliorates TNBS-induced colitis by regulating CD4+ T cells in mesenteric lymph nodes
by: Agustina Tri Endharti, et al.
Published: (2017-09-01)

TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection
by: Carla Usai, et al.
Published: (2020-06-01)

Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial
by: Jia Wang, et al.
Published: (2022-11-01)

Etanercept
by: Sibel Alper
Published: (2022-04-01)

TNF+ regulatory T cells regulate the stemness of gastric cancer cells through the IL13/STAT3 pathway
by: Rou Zhao, et al.
Published: (2023-07-01)

Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
by: Eugen Feist, et al.
Published: (2022-02-01)

Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients
by: Chamaida Plasencia-Rodríguez, et al.
Published: (2024-09-01)

Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α
by: Xian-Hua Jin, et al.
Published: (2019-06-01)

Microneedle-Assisted Transdermal Delivery of Etanercept for Rheumatoid Arthritis Treatment
by: Jian Cao, et al.
Published: (2019-05-01)

A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study
by: Jin Nakagawa, et al.
Published: (2017-08-01)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
by: Chen HH, et al.
Published: (2016-02-01)